723 related articles for article (PubMed ID: 34257548)
1. Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells.
Cruz-Rico G; Avilés-Salas A; Popa-Navarro X; Lara-Mejía L; Catalán R; Sánchez-Reyes R; López-Sánchez D; Cabrera-Miranda L; Aquiles Maldonado-Martínez H; Samtani-Bassarmal S; Arrieta O
Pathol Oncol Res; 2021; 27():597499. PubMed ID: 34257548
[No Abstract] [Full Text] [Related]
2. PD-L1 Expression in Non-Small-Cell Lung Cancer Including Various Adenocarcinoma Subtypes.
Miyazawa T; Marushima H; Saji H; Kojima K; Hoshikawa M; Takagi M; Nakamura H
Ann Thorac Cardiovasc Surg; 2019 Feb; 25(1):1-9. PubMed ID: 30282880
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of ≥ 50% PD-L1 expression with the SP263 monoclonal antibody in non-small cell lung cancer patients.
Li W; Song P; Guo L; Liu X; Guo C; Ying J; Gao S
Thorac Cancer; 2019 Feb; 10(2):175-182. PubMed ID: 30536734
[TBL] [Abstract][Full Text] [Related]
4. Real-World Prevalence of PD-L1 Expression Among Tumor Samples From Patients With Non-Small-Cell Lung Cancer.
Gelatti ACZ; Cordeiro de Lima VC; Freitas H; Werutsky G; Gaiger AM; Klock C; Viola PP; Shiang C; de Macedo MP; Lopes LF; De Marchi P; Albino da Silva EC; Moura F; Borges G; Zaffaroni F; Nunes Filho PR; Araujo LH; Mascarenhas E; Mathias C; Barrios C; Zukin M
Clin Lung Cancer; 2020 Nov; 21(6):e511-e515. PubMed ID: 32389509
[TBL] [Abstract][Full Text] [Related]
5. Solid histological component of adenocarcinoma might play an important role in PD-L1 expression of lung adenocarcinoma.
Miyazawa T; Morikawa K; Otsubo K; Sakai H; Kimura H; Chosokabe M; Furuya N; Marushima H; Kojima K; Mineshita M; Koike J; Saji H
Thorac Cancer; 2022 Jan; 13(1):24-30. PubMed ID: 34811933
[TBL] [Abstract][Full Text] [Related]
6. Expression of PD-L1, PD-L2, and IDO1 on tumor cells and density of CD8-positive tumor-infiltrating lymphocytes in early-stage lung adenocarcinoma according to histological subtype.
Takada K; Toyokawa G; Kinoshita F; Jogo T; Kohashi K; Wakasu S; Ono Y; Tanaka K; Oba T; Osoegawa A; Tagawa T; Azuma K; Okamoto I; Shimokawa M; Oda Y; Mori M
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2639-2650. PubMed ID: 32405745
[TBL] [Abstract][Full Text] [Related]
7. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
[TBL] [Abstract][Full Text] [Related]
8. Cytology cell blocks from malignant pleural effusion are good candidates for PD-L1 detection in advanced NSCLC compared with matched histology samples.
Zou Y; Xu L; Tang Q; You Q; Wang X; Ding W; Zhao J; Ren G
BMC Cancer; 2020 Apr; 20(1):344. PubMed ID: 32321471
[TBL] [Abstract][Full Text] [Related]
9. Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations.
Toki MI; Mani N; Smithy JW; Liu Y; Altan M; Wasserman B; Tuktamyshov R; Schalper K; Syrigos KN; Rimm DL
J Thorac Oncol; 2018 Dec; 13(12):1884-1896. PubMed ID: 30267840
[TBL] [Abstract][Full Text] [Related]
10. LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes.
He Y; Yu H; Rozeboom L; Rivard CJ; Ellison K; Dziadziuszko R; Suda K; Ren S; Wu C; Hou L; Zhou C; Hirsch FR
J Thorac Oncol; 2017 May; 12(5):814-823. PubMed ID: 28132868
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer.
Handa Y; Tsutani Y; Shiroma N; Kai Y; Mimae T; Miyata Y; Takeshima Y; Arihiro K; Okada M
Clin Lung Cancer; 2020 Jul; 21(4):e302-e314. PubMed ID: 32102750
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
[TBL] [Abstract][Full Text] [Related]
13. A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project.
Kerr KM; Thunnissen E; Dafni U; Finn SP; Bubendorf L; Soltermann A; Verbeken E; Biernat W; Warth A; Marchetti A; Speel EM; Pokharel S; Quinn AM; Monkhorst K; Navarro A; Madsen LB; Radonic T; Wilson J; De Luca G; Gray SG; Cheney R; Savic S; Martorell M; Muley T; Baas P; Meldgaard P; Blackhall F; Dingemans AM; Dziadziuszko R; Vansteenkiste J; Weder W; Polydoropoulou V; Geiger T; Kammler R; Peters S; Stahel R;
Lung Cancer; 2019 May; 131():95-103. PubMed ID: 31027705
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneous components of lung adenocarcinomas confer distinct EGFR mutation and PD-L1 expression.
Cai Y; Wu H; Shi X; Dong Y; Chang X; Zhang L; Zhou L; Su D; Yang M
BMC Cancer; 2020 Feb; 20(1):148. PubMed ID: 32093629
[TBL] [Abstract][Full Text] [Related]
15. Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers.
Hu C; Zhao L; Liu W; Fan S; Liu J; Liu Y; Liu X; Shu L; Liu X; Liu P; Deng C; Qiu Z; Chen C; Jiang Y; Liang Q; Yang L; Shao Y; He Q; Yu D; Zeng Y; Li Y; Pan Y; Zhang S; Shi S; Peng Y; Wu F
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887263
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of KRAS Mutation Subtypes and PD-L1 Expression in Patients With Lung Adenocarcinoma.
Tao L; Miao R; Mekhail T; Sun J; Meng L; Fang C; Guan J; Jain A; Du Y; Allen A; Rzeszutko BL; Socinski MA; Chang CC
Clin Lung Cancer; 2021 Jul; 22(4):e506-e511. PubMed ID: 32807653
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer.
Kim H; Kwon HJ; Park SY; Park Y; Park E; Chung JH
PLoS One; 2018; 13(6):e0198634. PubMed ID: 29856861
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of immune checkpoint inhibitors according to PD-L1 tumor proportion scores in non-small cell lung cancer.
Park S; Choi YD; Kim J; Kho BG; Park CK; Oh IJ; Kim YC
Thorac Cancer; 2020 Feb; 11(2):408-414. PubMed ID: 31841269
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological characteristics and tumor infiltrating immune cells associations of PD-L1 tumor expression in non-small cell lung cancer patients.
Aazzane O; Bakhtaoui FZ; Stitou S; Fellah H; Karkouri M
Tunis Med; 2024 Apr; 102(4):223-228. PubMed ID: 38746962
[TBL] [Abstract][Full Text] [Related]
20. Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas.
Driver BR; Miller RA; Miller T; Deavers M; Gorman B; Mody D; Ge Y; Barrios R; Bernicker E; Kim M; Cagle PT
Arch Pathol Lab Med; 2017 Nov; 141(11):1529-1532. PubMed ID: 28829153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
